Pitt Shield

Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery.

Authors: Oikari LE, Pandit R, Stewart R, Cuní-López C, Quek H, Sutharsan R, Rantanen LM, Oksanen M, Lehtonen S, de Boer CM, Polo JM, Götz J, Koistinaho J, White AR

The blood-brain barrier (BBB) presents a barrier for circulating factors, but simultaneously challenges drug delivery. How the BBB is altered in Alzheimer disease (AD) is not fully understood. To facilitate this analysis, we derived brain endothelial cells (iBECs) from human induced pluripotent stem cells (hiPSCs) of several patients carrying the familial AD PSEN1 mutation. We demonstrate that, compared with isogenic PSEN1 corrected and control iBECs, AD-iBECs exhibit altered tight and adherens junction protein expression as well as efflux properties. Furthermore, by applying focused ultrasound (FUS) that transiently opens the BBB and achieves multiple therapeutic effects in AD mouse models, we found an altered permeability to 3-5 kDa dextran as a model cargo and the amyloid-β (Aβ) peptide in AD-iBECs compared with control iBECs. This presents human-derived in vitro models of the BBB as a valuable tool to understand its role and properties in a disease context, with possible implications for drug delivery.

Introduction

Purpose drug delivery with BBB opening
Study Objective Investigate whether PSEN1 mutation alters brain endothelial cell phenotype and response to focused ultrasound-induced BBB opening using human iPSC-derived iBECs
Animal model / Human subject human induced pluripotent stem cell-derived brain endothelial cells (iBECs) from familial Alzheimer's disease patients (PSEN1 mutation) and isogenic controls
Disease model Alzheimer's disease (familial, PSEN1 ΔE9 mutation)
Cargo name and characteristics FITC-dextran (3-5 kDa) and FITC-Aβ42 (model cargo, not therapeutic)
Route of administration none (in vitro)

Outcomes and Safety

Summary of Outcomes AD-iBECs showed altered tight junction and efflux transporter expression, lower TEER, and increased claudin-5 expression. FUS+microbubbles (0.3 MPa, 20 ms burst period, 120 s) disrupted iBEC monolayer with recovery in controls but persistent permeability to dextran and Aβ42 in AD-iBECs at 24h post-FUS.
Duration of biological effect 24h
Safety-related matter No cell death or viability loss after FUS+MB treatment (MTT assay). Monolayer integrity recovered in control iBECs but not in AD-iBECs.

Brain Region

Visualization unavailable

Ultrasound Parameters

Ultrasound instrument Sonic Concepts H117 transducer
FUS Pressure 0.3 MPa or 0.15 MPa (peak rarefactional pressure)
FUS Mode pulsed
Duration of a single FUS session 120s
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search